|1.||Sacks, Frank M: 17 articles (07/2015 - 04/2003)|
|2.||Chan, Dick C: 11 articles (10/2015 - 08/2002)|
|3.||Barrett, P Hugh R: 11 articles (10/2015 - 08/2002)|
|4.||Watts, Gerald F: 11 articles (10/2015 - 08/2002)|
|5.||Alaupovic, Petar: 6 articles (05/2015 - 02/2005)|
|6.||Girelli, Domenico: 5 articles (01/2013 - 09/2002)|
|7.||Pizzolo, Francesca: 5 articles (01/2013 - 09/2002)|
|8.||Olivieri, Oliviero: 5 articles (01/2013 - 09/2002)|
|9.||Ooi, Esther M M: 5 articles (04/2011 - 05/2008)|
|10.||Kawakami, Akio: 5 articles (11/2010 - 08/2006)|
08/01/2011 - "Hypertriglyceridemia and delayed clearance of fat load in transgenic rabbits expressing human apolipoprotein CIII."
03/01/2006 - "In the first pharmacogenetic study of its kind in HIV-1 disease, we found race/ethnic-specific differences in plasma lipid levels on ART, as well as differences in the influence of the apoC-III gene on the development of PI-related hypertriglyceridemia. "
08/01/1996 - "In a large sample of individuals from the ARIC study, six polymorphic markers were typed and plasma lipid values were measured to determine whether the well-established association between the Sst I S2 allele in the 3'-untranslated region of the apo C-III gene and hypertriglyceridemia was due to disequilibrium with variation in the 5' regulatory region of the apo C-III gene. "
07/30/2015 - "Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia."
04/01/2015 - "This year, two large-scale epidemiological studies have linked mutations in apoC-III with increased incidence of CVD and hypertriglyceridemia. "
04/01/2011 - "Altered plasma apoC-III metabolism is a feature of dyslipidemia in moderate CKD. "
12/01/2009 - "Altered apoC-III metabolism may contribute to dyslipidemia in CKD, and this requires further investigation."
09/01/2006 - "We examined this relationship, and the association of apo C-III with dyslipidemia, in a triethnic sample of 168 subjects with normoglycemia or type 2 diabetes. "
08/01/1994 - "The disproportional distribution of the variant apoC-III isoproteins may indicate differences in the metabolism of variant and normal apoC-III. We conclude that genetically determined structural variants of apoC-III with changes in complete net charges are very rare and, hence, do not significantly contribute to the formation of dyslipidemia in the German population. "
07/01/1999 - "Understanding the mechanism(s) of elevated apoC-III in uremia may help to clarify the causes of uremic dyslipidemia."
04/01/2012 - "Apo C-III levels were 25% higher in subjects with cleared infection versus those with active infection (p = 0.009). "
05/01/2008 - "ApoC-III is the first reported candidate biomarker in plasma associated with the spontaneous resolution of HCV infection."
08/01/2013 - "In a cell-based system, treatment with VLDL and LVPs reversed the LPL-mediated inhibition of HCV infection in apoC-III/-IV-dependent manners. "
05/01/2008 - "ApoC-III was found to be higher in donors who had resolved their HCV infection than in donors with chronic infection, results which were consistent with SELDI-TOF-MS data. "
05/01/2008 - "Identification of apolipoprotein C-III as a potential plasmatic biomarker associated with the resolution of hepatitis C virus infection."
06/01/2001 - "Determination of the apoC-III concentration during the peripartum period is suggested to be helpful in diagnosing milk fever. "
06/01/2001 - "The purpose of the present study was to examine whether the apoC-III concentration in healthy cows is altered during the peripartum period, to assess the usefulness of apoC-III as a marker for milk fever. "
06/01/2001 - "The decrease was most distinct in milk fever, thereby suggesting that apoC-III is particularly relevant to the development of milk fever and also that apoC-III is a candidate diagnostic marker for this disease. "
06/01/2001 - "Concentrations of apolipoprotein C-III in healthy cows during the peripartum period and cows with milk fever."
03/01/2001 - "The decrease in the apoC-III concentration is suggested to be closely associated with the postparturient disorders, in particular with milk fever."
|5.||Body Weight (Weight, Body)
10/01/2005 - "In contrast, ad libitum consumption of the high-MUFA diet also resulted in a significant reduction in body weight (-2.3%, P < .01) as well as in significant reductions in plasma apo C-III (-11%, P = .05) and fasting plasma TG (-17%, P < .01). "
10/01/2005 - "Ad libitum consumption of the high-CHO diet induced a significant reduction in body weight (-2.6%, P < .0001), but had no impact on plasma apo C-III concentrations and on fasting and postprandial plasma TG levels. "
08/01/2004 - "These results suggest that increased hepatic production of VLDL apoC-III is characteristic of subjects with higher body weights and lower levels of insulin sensitivity and is strongly related to the plasma concentration and level of production of VLDL TG."
08/01/2004 - "To investigate the role of apolipoprotein (apo)C-III metabolism in the etiology of hypertriglyceridemia in these individuals, we investigated 10 male subjects with different body weights (body mass index, 24-34 kg/m(2)) and insulin sensitivity (homeostasis model assessment, 4.7-35.0). "
08/01/2004 - "Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity."
|2.||Apolipoproteins E (ApoE)
|3.||Apolipoprotein A-I (Apolipoprotein A1)
|5.||Proteins (Proteins, Gene)
|6.||3' Untranslated Regions (3' UTR)
|8.||Apolipoproteins C (ApoC)
|9.||Lipoprotein Lipase (Diacylglycerol Lipase)
|1.||Transplantation (Transplant Recipients)
|2.||Highly Active Antiretroviral Therapy (HAART)